Raltegravir: The evidence of its therapeutic value in HIV-1 infection.
about
HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy.Design, Synthesis, and Biological Evaluation of 1,2-Dihydroisoquinolines as HIV-1 Integrase Inhibitors.Divalent metals and pH alter raltegravir disposition in vitro.
P2860
Raltegravir: The evidence of its therapeutic value in HIV-1 infection.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Raltegravir: The evidence of its therapeutic value in HIV-1 infection.
@ast
Raltegravir: The evidence of its therapeutic value in HIV-1 infection.
@en
type
label
Raltegravir: The evidence of its therapeutic value in HIV-1 infection.
@ast
Raltegravir: The evidence of its therapeutic value in HIV-1 infection.
@en
prefLabel
Raltegravir: The evidence of its therapeutic value in HIV-1 infection.
@ast
Raltegravir: The evidence of its therapeutic value in HIV-1 infection.
@en
P2860
P356
P1433
P1476
Raltegravir: The evidence of its therapeutic value in HIV-1 infection
@en
P2093
Kavya Ramkumar
Nouri Neamati
P2860
P304
P356
10.2147/CE.S6004
P407
P577
2010-06-15T00:00:00Z